Toborzás még nem indult2. fázis
Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
A legfontosabb adatok
- Ki végzi
- Azienda Ospedaliera Universitaria Integrata Verona
- Hol
- Olaszország2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2026. szept. 30.
- Várható befejezés
- 2028. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. augusztus 14.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for men aged 50 or older and post-menopausal women with osteoporosis and erosive hand osteoarthritis. They must never have had osteoporosis medicine and must be able to start denosumab or zoledronic acid.
- Életkor
- Men ≥50 years; post-menopausal women (record minimum age 18 Years)
- Nem
- Men and post-menopausal women
- A betegség stádiuma
- Erosive (inflammatory) hand osteoarthritis with past inflammatory flares and current signs of inflammation in the finger joints. At least 1 finger joint must look like a 'J' or 'E' phase joint on X-ray. Osteoporosis must also be present.
- Korábbi kezelés
- No earlier anti-osteoporosis medicine. No IV bisphosphonates ever, no oral bisphosphonates within 12 months before screening, no denosumab ever, and no other drugs like romosozumab, PTH analogs or SERMs.
- Biomarker vagy leletérték
- Bone density (BMD) T-score of ≤ -2.5 at the lumbar spine, total hip or femoral neck, or a T-score of ≤-2.0 there plus an existing major osteoporotic (MOF) fracture.
A részvétel fő kizáró okai
- Cancer within the last 5 years, except some skin cancers or cervical carcinoma in situ
- Other inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis or gout
- Past or active jaw bone death (ONJ), active dental infection or unhealed mouth surgery
- Kidney filtration (eGFR) < 35 mL/minute/1.73 m^2, low blood calcium or vitamin D < 20 ng/mL (<49.9 nmol/L)
- Past solid organ or bone marrow transplant, or other bone diseases
A regiszter feltételei, szó szerint
Mind a 34 feltétel megnézéseKevesebb
Ki vehet részt
- Men ≥50 years of age and post-menopausal women with osteoporosis naïve to any anti-osteoporosis medication candidate to treatment to either denosumab of zoledronic acid
- Subjects with hand OA having suffered from transient inflammatory attacks of the interphalangeal finger joints characteristic for what has been termed ‘inflammatory’ or ‘erosive’ hand OA
- Subjects with hand OA showing inflammatory signs, either clinically or ultrasonographically, of the interphalangeal finger joints
- Subjects with hand OA in which at least 1 interphalangeal finger joint has the typical appearance on the X-rays of a ‘J’ or ‘E’ phase joint as defined by the criteria mentioned above
- Able and willing to give written informed consent and to comply with the requirements of the study protocol
- A baseline BMD T-score of ≤ -2.5 at the lumbar spine, total hip, or femoral neck or baseline T-score of ≤-2.0 at the lumbar spine, total hip, or femoral neck + a prevalent MOF fracture
- Signed informed consent for participation in the study and for the processing of personal data
Ki nem vehet részt
- No past IV bisphosphonates at any time, or any oral bisphosphonate use within 12 months before screening
- No past treatment with denosumab
- Recipient of an investigational drug within 4 weeks prior to study drug administration or within 5 half-lives of the investigational drug, whichever is longer
- No past treatment with other anti-osteoporosis medications (romosozumab, PTH analogs, SERMs etc.)
- Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma or localized squamous cell carcinoma of the skin)
- Contraindication to, or poorly tolerant of denoosumab therapy (including hypersensitivity to the drug and any excipients)
- Contraindication to, or poorly tolerant of zoledronic acid therapy (including hypersensitivity to the drug and any excipients)
- History of atypical femur fracture
- Unstable systemic medical condition
- History of Addison disease
- History of osteomalacia
- History of osteonecrosis of the jaw (ONJ)
- History or presence of inflammatory or erosive arthritides other than erosive hand osteoarthritis (EHOA), including rheumatoid arthritis, psoriatic arthritis, crystal-induced arthritis, connective tissue disease-related arthritis, and spondyloarthritis
- Active osteonecrosis of the jaw (ONJ), unhealed oral surgery, active dental infection, or planned urgent invasive dental procedure that is considered incompatible with safe initiation of study treatment
- History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition
- History of Paget’s disease of bone
- Other bone diseases which affect bone metabolism
- History of any solid organ or bone marrow transplant
- Intolerance to calcium supplements, vitamin D supplements
- Hypercalcemia >10% above upper limit of normal (ULN)
- Elevated transaminases or total bilirubin ≥ 2.0 x ULN
- Hypocalcemia below lower limit of normal (LLN)
- Estimated glomerular filtration rate < 35 mL/minute/1.73 m^2 at the time of screening/randomization
- Not a good candidate for study participation in opinion of investigator
- Uncontrolled hyperthyroidism
- Uncontrolled hypothyroidism
- Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To demonstrate the reduction in the progression of erosion volume in the denosumab group vs zoledronic acid group
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. augusztus 14.